1)日本鉄バイオサイエンス学会治療指針作成委員会(編):鉄剤の適正使用による貧血治療指針(改訂第2版),響文社,2009
2)Okada S, Midorikawa O:Induction of the rat renal adenocarcinoma by Fe-nitrilotriacetate(Fe-nta). Jpn Arch Intern Med 29:485-491, 1982
3)Kato J, et al:Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702, 2001
4)Hayashi H, et al:Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22:268-271, 1995
5)厚生労働省科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班(研究代表者:小澤敬也):輸血後鉄過剰症の診療ガイド,2008 http://www.jichi.ac.jp/zoketsushogaihan/tetsufinal.pdf
6)Park CH, et al:Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806-7810, 2001
7)Tomosugi N, et al:Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108:1381-1387, 2006
8)Kawabata H, et al:Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92:857-858, 2007
9)Greenberg PL, et al:Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
10)Sakamoto S, et al:Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97:109-116, 2013
11)日本透析医学会 第二次腎性貧血治療ガイドライン作成ワーキンググループ:慢性腎臓病患者における腎性貧血治療のガイドライン.透析会誌41:661-716, 2008
12)Gandon Y, et al:Non-invasive assessment of hepatic iron stores by MRI. Lancet 363:357-362, 2004
13)Hayashi H, et al:Genetic background of Japanese patients with adult-onset storage diseases in the liver. Hepatol Res 37:777-783, 2007